View Future GrowthRaphael Pharmaceutical 過去の業績過去 基準チェック /06Raphael Pharmaceutical は平均年間 5% の収益成長を遂げていますが、Biotechs 業界では年間 収益成長率 となっています。33.8% です。主要情報4.97%収益成長率16.29%EPS成長率Biotechs 業界の成長17.04%収益成長率n/a株主資本利益率n/aネット・マージンn/a前回の決算情報31 Mar 2026最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • Nov 19Raphael Pharmaceutical Inc. Announces Filing of Provisional Patent Application for the Treatment of Neutrophil-Dominant Autoimmune Diseases, Including Rheumatoid ArthritisR Raphael Pharmaceutical Inc. announced the filing of a provisional patent application with the United States Patent and Trademark Office. The application covers the use of the Company's highly purified cannabinoid-based technology platform in the treatment of neutrophil-dominant autoimmune diseases, including its lead product candidate for rheumatoid arthritis (RA), as well as psoriatic arthritis, inflammatory bowel disease, systemic lupus erythematosus with neutrophil involvement, and gout. Raphael previously announced positive proof-of-concept clinical study results for its cannabinoid-based formula for the management of RA. The study was successfully completed in the United States under Institutional Review Board ("IRB") approval and in compliance with U.S. Food and Drug Administration ("FDA") regulations. No adverse effects were reported throughout the trial. The provisional patent application, titled, "R Raphael Pharmaceutical Inc. /Rambam MedTech Formula for Treating Neutrophil-Dominant Autoimmune Diseases (including RA)" (No. 63/911,729), was filed jointly with the Medical Cannabis Research and Innovation Center (MCRIC) at Rambam Health Care Campus - one of the world's leading university hospitals. Raphael and Rambam have collaborated under a sponsored research agreement signed in 2019, granting Raphael exclusive access to Rambam's world-class cannabinoid research and development program, led by Dr. Igal Louria-Hayon, who serves as both Chief Technology Officer (CTO) of Raphael and Head of the Medical Cannabis Research and innovation Center at Rambam Health Care campus. Dr. Louria-Hayon is a global expert in cannabinoid research and cell-to-cell communication. Key Findings from the Proof-of-Concept Clinical Study: Raphael Pharmaceutical utilizes a highly purified cannabinoid formulation derived from the hemp plant, entirely free of psychoactive cannabis components, with exceptional anti-inflammatory potential. The formulation is administered orally and demonstrated no side effects. It is designed to interact with the human endocannabinoid system by activating cannabinoid receptors expressed on immune cells. In 2025, the Company announced positive Proof-of-Concept clinical results for the use of its cannabinoid-based formula in the treatment of RA. The eight-week IRB-approved study conducted in the United States showed significant improvements in pain, sleep quality, and overall well-being, which became evident as early as week four and persisted through the end of the trial. This included a reduction in DAS28 scores from high disease activity to moderate disease severity.お知らせ • Jan 07Raphael Pharmaceutical Inc. Announces Positive Proof-Of-Concept Clinical Study Results for the Company's Cannabinoid-Based Formula for the Treatment of Rheumatoid ArthritisR Raphael Pharmaceutical Inc. announced positive proof-of-concept clinical study results for the Company's cannabinoid-based formula for the management of rheumatoid arthritis ("RA"). Citruslabs, a leading contract research organization, successfully completed this proof-of- concept clinical study in the United States under Institutional Review Board ("IRB") approval and in compliance with U.S. Food and Drug Administration ("FDA") regulations. Key Findings of the Proof-of-Concept Clinical Study: The single-group clinical trial evaluated the effects of Raphael Pharmaceutical's highly purified cannabinoid-based formula on RA and involved 12 adult participants, each of whom used 0.5 mL of the formula daily over an eight-week period. The study results demonstrate promising efficacy, with significant improvements observed in critical health outcomes, including pain levels, sleep quality, and overall well-being. These benefits became evident as early as Week 4 and were sustained through the end of the trial. The study's key findings: Reduction in Disease Activity Score ("DAS28"): DAS28, a comprehensive metric assessing RA disease activity, declined by 19.2%, reflecting a shift in participants from high to moderate disease activity. DAS28 is a widely used measure of RA disease activity that combines the number of tender and swollen joints, levels of inflammation, and the patient's self-assessed health. A lower DAS28 score indicates reduced disease activity, and achieving low scores is a key goal in RA management. Of note, among the data: Participants in remission increased from 0% at baseline to 16.67% by Week 8. The Company intends to protect its intellectual property and highly purified cannabinoid formulation with a registered patent.お知らせ • Jan 01Raphael Pharmaceutical Inc. Receives Clinical Study Results After Successful Completion of a Proof-Of-Concept Clinical StudyOn December 23, 2024, Raphael Pharmaceutical Inc. (“Raphael” or the “Company”) received clinical study results after a successful completion of a proof-of-concept clinical study (the “Study”), evaluating the efficacy of the Company’s Cannabinoid based formula (“Raphael’s Formula”) in patients with active Rheumatoid Arthritis (“RA”). The single-group Study was managed by MindMate Inc./dba Citruslabs (“Citruslabs”) and conducted in Santa Monica, California, United States, under Institutional Review Board (“IRB”) approval, in compliance with the United States Food and Drug Administration (the “FDA”) regulations and in accordance with applicable industry standards and regulations. The Study evaluated the impact of Raphael’s Formula on RA related health outcomes in 12 adult participants, each of whom used 0.5 mL Raphael’s Formula product daily at home over an 8-week period, completed questionnaires and attended their local Quest Diagnostics Center for blood biomarker testing at designated intervals. According to the Study results, the questionnaires results demonstrated significant improvement in certain health parameters, including pain levels, sleep quality and overall well-being, with certain parameters remaining significantly improved through the end of the Study. The key findings from the Study results included a reduction in the Disease Activity Score (a comprehensive metric assessing RA disease activity) (“DAS28”) by 19.2%, reflecting a total decrease from high to moderate disease activity. A low DAS28 score indicates reduced disease activity and is a key goal in RA management. Additionally, the percentage of participants classified according to disease activity was evaluated and the findings included an increase in the percentage of participants classified as in remission from 0% at baseline to 16.67% at week 8, an increase in the percentage of participants classified as having low disease activity from 8.33% to 16.67% and a decreased in the percentage of participants classified as having high disease activity from 66.67% at baseline to 41.67% at week 8. The Study results also showed an improvement in health-related parameters, as evaluated through the questionnaires. For example, pain levels dropped from 75% participants reporting a negative result to 50% in week 8 and morning stiffness showed a notable reduction from 75% participants reporting such symptom at baseline to 41.67% at week 8. Additionally, participant perceptions were highly positive, with approximately 83.3% of participants willing to continue using the product and approximately 91.7% of participants indicating they would recommend Raphael’s Formula to others with RA.お知らせ • May 27Raphael Pharmaceutical Inc. Contemplates Bankruptcy Raphael Pharmaceutical Inc. is contemplating filing for bankruptcy, as of May 25, 2023. According to company press release, the company said that additional funding will be required to complete the Company’s research and development and clinical trials, to attain regulatory approvals, to begin the commercialization efforts of the Company’s product and to achieve a level of sales adequate to support the Company’s cost structure. If such sufficient financing is not received timely, the Company will not have sufficient cash flows and liquidity to finance its business operations as currently contemplated and would then need to pursue a plan to license its assets, seek to be acquired by another entity, cease operations or seek bankruptcy protection.収支内訳Raphael Pharmaceutical の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:RAPH 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Mar 260-10131 Dec 250-11130 Sep 250-11030 Jun 250-11131 Mar 250-11031 Dec 240-21130 Sep 240-11030 Jun 240-11131 Mar 240-21131 Dec 230-11130 Sep 230-31230 Jun 230-32131 Mar 230-32131 Dec 220-32130 Sep 220-32130 Jun 220-21131 Mar 220-21131 Dec 210-21130 Sep 210-11130 Jun 210-10131 Mar 210-10131 Dec 200-100質の高い収益: RAPHは現在利益が出ていません。利益率の向上: RAPHは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: RAPHは利益を出していないが、過去 5 年間で年間5%の割合で損失を削減してきた。成長の加速: RAPHの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: RAPHは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 43% ) と比較することは困難です。株主資本利益率高いROE: RAPHの負債は資産を上回っているため、自己資本利益率を計算することは困難です。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/27 05:55終値2026/04/29 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Raphael Pharmaceutical Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Nov 19Raphael Pharmaceutical Inc. Announces Filing of Provisional Patent Application for the Treatment of Neutrophil-Dominant Autoimmune Diseases, Including Rheumatoid ArthritisR Raphael Pharmaceutical Inc. announced the filing of a provisional patent application with the United States Patent and Trademark Office. The application covers the use of the Company's highly purified cannabinoid-based technology platform in the treatment of neutrophil-dominant autoimmune diseases, including its lead product candidate for rheumatoid arthritis (RA), as well as psoriatic arthritis, inflammatory bowel disease, systemic lupus erythematosus with neutrophil involvement, and gout. Raphael previously announced positive proof-of-concept clinical study results for its cannabinoid-based formula for the management of RA. The study was successfully completed in the United States under Institutional Review Board ("IRB") approval and in compliance with U.S. Food and Drug Administration ("FDA") regulations. No adverse effects were reported throughout the trial. The provisional patent application, titled, "R Raphael Pharmaceutical Inc. /Rambam MedTech Formula for Treating Neutrophil-Dominant Autoimmune Diseases (including RA)" (No. 63/911,729), was filed jointly with the Medical Cannabis Research and Innovation Center (MCRIC) at Rambam Health Care Campus - one of the world's leading university hospitals. Raphael and Rambam have collaborated under a sponsored research agreement signed in 2019, granting Raphael exclusive access to Rambam's world-class cannabinoid research and development program, led by Dr. Igal Louria-Hayon, who serves as both Chief Technology Officer (CTO) of Raphael and Head of the Medical Cannabis Research and innovation Center at Rambam Health Care campus. Dr. Louria-Hayon is a global expert in cannabinoid research and cell-to-cell communication. Key Findings from the Proof-of-Concept Clinical Study: Raphael Pharmaceutical utilizes a highly purified cannabinoid formulation derived from the hemp plant, entirely free of psychoactive cannabis components, with exceptional anti-inflammatory potential. The formulation is administered orally and demonstrated no side effects. It is designed to interact with the human endocannabinoid system by activating cannabinoid receptors expressed on immune cells. In 2025, the Company announced positive Proof-of-Concept clinical results for the use of its cannabinoid-based formula in the treatment of RA. The eight-week IRB-approved study conducted in the United States showed significant improvements in pain, sleep quality, and overall well-being, which became evident as early as week four and persisted through the end of the trial. This included a reduction in DAS28 scores from high disease activity to moderate disease severity.
お知らせ • Jan 07Raphael Pharmaceutical Inc. Announces Positive Proof-Of-Concept Clinical Study Results for the Company's Cannabinoid-Based Formula for the Treatment of Rheumatoid ArthritisR Raphael Pharmaceutical Inc. announced positive proof-of-concept clinical study results for the Company's cannabinoid-based formula for the management of rheumatoid arthritis ("RA"). Citruslabs, a leading contract research organization, successfully completed this proof-of- concept clinical study in the United States under Institutional Review Board ("IRB") approval and in compliance with U.S. Food and Drug Administration ("FDA") regulations. Key Findings of the Proof-of-Concept Clinical Study: The single-group clinical trial evaluated the effects of Raphael Pharmaceutical's highly purified cannabinoid-based formula on RA and involved 12 adult participants, each of whom used 0.5 mL of the formula daily over an eight-week period. The study results demonstrate promising efficacy, with significant improvements observed in critical health outcomes, including pain levels, sleep quality, and overall well-being. These benefits became evident as early as Week 4 and were sustained through the end of the trial. The study's key findings: Reduction in Disease Activity Score ("DAS28"): DAS28, a comprehensive metric assessing RA disease activity, declined by 19.2%, reflecting a shift in participants from high to moderate disease activity. DAS28 is a widely used measure of RA disease activity that combines the number of tender and swollen joints, levels of inflammation, and the patient's self-assessed health. A lower DAS28 score indicates reduced disease activity, and achieving low scores is a key goal in RA management. Of note, among the data: Participants in remission increased from 0% at baseline to 16.67% by Week 8. The Company intends to protect its intellectual property and highly purified cannabinoid formulation with a registered patent.
お知らせ • Jan 01Raphael Pharmaceutical Inc. Receives Clinical Study Results After Successful Completion of a Proof-Of-Concept Clinical StudyOn December 23, 2024, Raphael Pharmaceutical Inc. (“Raphael” or the “Company”) received clinical study results after a successful completion of a proof-of-concept clinical study (the “Study”), evaluating the efficacy of the Company’s Cannabinoid based formula (“Raphael’s Formula”) in patients with active Rheumatoid Arthritis (“RA”). The single-group Study was managed by MindMate Inc./dba Citruslabs (“Citruslabs”) and conducted in Santa Monica, California, United States, under Institutional Review Board (“IRB”) approval, in compliance with the United States Food and Drug Administration (the “FDA”) regulations and in accordance with applicable industry standards and regulations. The Study evaluated the impact of Raphael’s Formula on RA related health outcomes in 12 adult participants, each of whom used 0.5 mL Raphael’s Formula product daily at home over an 8-week period, completed questionnaires and attended their local Quest Diagnostics Center for blood biomarker testing at designated intervals. According to the Study results, the questionnaires results demonstrated significant improvement in certain health parameters, including pain levels, sleep quality and overall well-being, with certain parameters remaining significantly improved through the end of the Study. The key findings from the Study results included a reduction in the Disease Activity Score (a comprehensive metric assessing RA disease activity) (“DAS28”) by 19.2%, reflecting a total decrease from high to moderate disease activity. A low DAS28 score indicates reduced disease activity and is a key goal in RA management. Additionally, the percentage of participants classified according to disease activity was evaluated and the findings included an increase in the percentage of participants classified as in remission from 0% at baseline to 16.67% at week 8, an increase in the percentage of participants classified as having low disease activity from 8.33% to 16.67% and a decreased in the percentage of participants classified as having high disease activity from 66.67% at baseline to 41.67% at week 8. The Study results also showed an improvement in health-related parameters, as evaluated through the questionnaires. For example, pain levels dropped from 75% participants reporting a negative result to 50% in week 8 and morning stiffness showed a notable reduction from 75% participants reporting such symptom at baseline to 41.67% at week 8. Additionally, participant perceptions were highly positive, with approximately 83.3% of participants willing to continue using the product and approximately 91.7% of participants indicating they would recommend Raphael’s Formula to others with RA.
お知らせ • May 27Raphael Pharmaceutical Inc. Contemplates Bankruptcy Raphael Pharmaceutical Inc. is contemplating filing for bankruptcy, as of May 25, 2023. According to company press release, the company said that additional funding will be required to complete the Company’s research and development and clinical trials, to attain regulatory approvals, to begin the commercialization efforts of the Company’s product and to achieve a level of sales adequate to support the Company’s cost structure. If such sufficient financing is not received timely, the Company will not have sufficient cash flows and liquidity to finance its business operations as currently contemplated and would then need to pursue a plan to license its assets, seek to be acquired by another entity, cease operations or seek bankruptcy protection.